Comparative anticancer effects of vaccination and dietary factors on experimentally-induced cancers

In Vivo

Volumn 12, Issue 6, 1998, Pages 675-689

  Zusman, Igor ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Apoptosis; Colon cancer; Fatty acids; High fat diets; High fiber diets; Lymph system; Mammary glands cancer; p53 protein

Indexed keywords

1,2 DIMETHYLHYDRAZINE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; BETA GLUCURONIDASE; CANCER VACCINE; CELLULOSE; CYCLINE; IMMUNOGLOBULIN G ANTIBODY; MONOUNSATURATED FATTY ACID; OLEIC ACID; OLIVE OIL; ORNITHINE DECARBOXYLASE; PALMITIC ACID; POLYUNSATURATED FATTY ACID; PROTEIN P53; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER; CANCER IMMUNIZATION; CANCER PREVENTION; COLON CANCER; DIET; EXPERIMENTAL NEOPLASM; HIGH FIBER DIET; IMMUNOSTIMULATION; LIPID DIET; LYMPHOBLAST; NONHUMAN; PLASMA CELL; REVIEW;

EID: 0032438266     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Furihata M, Sonobe H and Ohtsuki Y: The aberrant p53 protein (Review). Int J Oncol 6: 1209-1226, 1995.
2. Sidransky D and Hollstein M: Clinical implications of the p53 gene. Ann Rev Med 47: 227-232, 1996.
3. Willett WC: Epidemiologic studies of diet and cancer. Med Oncol Tumor Pharmacother 7: 93-97, 1990.
4. Hill P: It is not what you eat, but how you eat it: Digestion, life-style, nutrition. Nutrition 7: 385-395, 1991.
5. Cohen J: Cancer vaccines get a shot in the arm. Science 262: 841-843, 1993.
6. Stevenson FK: Update of tumor vaccines. Int J Clin Lab Res 22: 84-89, 1992.
7. Ben-Natan D: Stress and infectious diseases. Isr J Vet Med 49: 105-112, 1994.
8. Lane DP, Benchimol S: p53: oncogene or anti-oncogene? Genes Dev 4: 18, 1990.
9. Rotter V and Prokocimer M: p53 and human malignancies. Advan Cancer Res 7: 257-273, 1991.
10. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
11. Zusman I: The clinical relevance of p53 oncoprotein determination in cancer diagnosis and prognosis (Review). Oncol Rep 2: 143-150, 1995.
12. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AKC: Cytoplasmic accumulation of p53 protein - an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86: 681-687, 1994.
13. Sepehrnia B, Paz IB, Dasgupta G, Momand J: Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 271: 15084-15090, 1996.
14. Flamini G, Curigliano G, Ratto C Astone A, Ferretti G, Nucera P, Sofo L, Sgambato A, Boninsegna A, Crucitti F, Cittadini A: Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 32A: 802-806, 1996.
15. Boring CC, Squires TS, Tong T: Cancer statistics. CA - Cancer J Clin 43: 7-26, 1993.
16. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW, Melton LJ: Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 60: 2318-2324, 1987.
17. Pilipshen SJ, Heiweil M, Quan SUQ, Sternberg SS, Enker WE: Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 53: 1354-1362, 1984.
18. Cohen AM, Shank B, Friedman MA: Colorectal cancer. In: Cancer, Principles and Practice of Oncology. DeVitta VTJr, Hellman S, Rosenberg SA (eds.). Ed.3, Philadelphia, JB Lippincott Co. pp. 895-964, 1989.
19. Boring CC, Squires TS, Tong T: Cancer statistics, 1991. CA Cancer J Clin 42: 19-38, 1992.
20. Wattenberg DW: Prevention-therapy-basic science and the resolution of the cancer problem: presidential address. Cancer Res 53: 5890-5896, 1993.
21. Steplewski Z: Advances and outlooks for immunotherapy of cancer. Hybrydoma 12: 493-500, 1993.
22. Stigbrand T, Ullen A, Sandstrom P, Mirzaiejoniani H, Sundstrom B, Nilsson B, Arlestig L, Norrlund RR, Ahlstrom KR, Hietala SO: Twenty years with monoclonal antobodies - State of the art. Where do we go? Acta Oncol 35: 259-265, 1996.
23. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 94: 297-312, 1993.
24. Canevari S, Pupa SM, Menard S: 1975-1995 revised anti-cancer serological response: Biological significance and clinical implications. Annals Oncol 7: 227-232, 1996.
25. James K: Therapeutic monoclonal antibodies - their production and application. Anim Cell Biotechnol 4: 206-252, 1990.
26. Bhattacharya-Chatterjee M, Foon KA: Idiotypic- monoclonal antibodies as vaccines for human cancer. Intern Rev Immunol 7;. 289-302, 1991.
27. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Shedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, Koprowski H: Anti-idiotype immunization of cancer patients: modulation of immune response. Proc Natl Acad Sci USA 84: 8055-8059, 1987.
28. Mellstedt H, Frodin JE, Masucci G, Ragnhammar P, Fagerberg J, Hjelm AL, Wersall P, Osterborg A: The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 18: 462-477, 1991.
29. Fagerberg J, Frodin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H: Immunization effect of monoclonal antibodies against tumor-associated antigens during cancer treatment. Annals NY Acad Sci 690: 337-339, 1993.
30. Sears HG, Herlyn D, Steplewski Z, Koprowski H: Effects of monoclonal antibody immunotherapy in patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 3: 138-150, 1984.
31. Meredith RF, Khazaeli MB, Plott WE, Brezovich IA, Russell CD, Wheeler RH, Spencer SA, Lobuglio AF: Phase I trial of iodine-131 -chimeric B72.3 (human IgG 4) in metastatic colorectal cancer. J Nucl Med 33: 23-29, 1992.
32. Bamias A, Epenetos AA: Two-step strategies for the diagnosis and treatment of cancer with bioconjugates. Antibody Immunocon Radiopharm 5: 385-395, 1992.
33. Herlyn D, Linnebach A, Koprowski H, Herlyn M: Epitope- and antigen-specific cancer vaccines. Int Rev Immunol 7: 245-257, 1991.
34. Herlyn D, Zaloudik J, Somasundaram R, Jacob L, Harris D, Kieny MP, Sears H: Anti- idiotype vaccine in colorectal cancer patients. Hybridoma 12: 515-520, 1993.
35. Zusman I, Zusman R, Korol D, Gurevich P: IgG generated against benign tumor- associated antigens prevented the effects of 1,2-Dimethylhydrazine in rats. Anticancer Res 16: 1183-1186, 1996.
36. Zusman I, Zusman R, Korol D: Isolation of tumor-associated antigens from sera of cancerous rats using of polyclonal IgG entrapped in gel fiberglass columns. Oncol Rep 1: 751-754, 1994.
37. Zusman I, Zusman R, Gurevich P, Korol D, Tendler Y: High tumor-preventive effects of polyclonal IgG generated against p53 tumor-associated protein obtained from benign tumor-bearing rats. Oncol Rep 3: 975-979, 1996.
38. Kastan MB, Canman CE, Leonard CJ: P53, cell cycle control and apoptosis: Implication for cancer. Cancer Metast Rev 14: 3-15, 1995.
39. Koshland DEJr: Molecule of the year. Science 262: 1953, 1993.
40. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
41. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329: 1318-1327, 1993.
42. Milner J: Forms and function of p53. Cancer Biol 5: 211-219, 1994.
43. Lane DP: A death in the life of p53. Nature 362: 786-787, 1993.
44. Donehower LA: Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Biochim Biophys Acta 1242: 171-176, 1996.
45. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84: 2391-2411, 1994.
46. Tendler Y, Reshef R, Cohen I, Barzilai M, Shasha SM, Rotter V, Shkolnik T: Histochemical studies of progressive p53 mutations during colonic carcinogenesis in Sprague-Dawley rats induced by N-methyl-N-nitro-N-nitrosoguanidine or azoxymethane. Pathobiol 62: 232-237, 1994.
47. Diamandis EP: Clinical applications of the p53 tumor suppressor gene. Clinica Chimica Acta 237: 79-90, 1995.
48. Shaulsky G, Goldfinger N, Rotter V: Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 51: 5232-5237, 1991.
49. Finlay CA, Hinds PW, Levine AJ: The p53 protooncogene can act as a supressor of transformation. Cell 53: 1083-1093, 1989.
50. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
51. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458-1462, 1994.
52. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, Bellet D, Guillet JG, Bressacdepaillerets B: Primary proliferative T cell response to wildtype p53 protein in patients with breast cancer. Eur J Immunol 25: 1765-1769, 1995.
53. Banerjee D, Lenz HJ, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Denenberg P, Bertino JR: Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Different 6: 1405-1413, 1995.
54. Li BL, Kittrell FS, Medina D, Rosen JM: Delay of dimethylbenz(a) antracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Molec Carcinogen 14: 75-83, 1995.
55. Okamoto M, Ohtsu H, Komonami R, Yonekawa H: Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in FI hybrid mice. Carcinogenesis 16: 2659-2666, 1995.
56. Zusman I, Gurevich P, Sandier B, Zusman R, Smirnoff P, Tendler Y. Tumor- suppressor effects of anti-p53 IgG on chemically induced colon cancer in rats. Cancer J10: 116-120, 1997.
57. Boon T, Bruggen van der P: Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725-729, 1996.
58. Tendler Y, Ben-Hur H, Gurevich P, Berman V, Sandier B, Nyska A, Zion H, Zinder O, Zusman I: Role of apoptosis, proliferating cell nuclear antigen and p53 protein in the immune response of the rat colon cells to cancer and vaccination with the anti-p53 polyclonal IgG. Anticancer Res 17: 4653-3658, 1997.
59. Ben-Hur H, Gurevich P, Berman V, Tendler Y, Sandler B, Zion H, Zinder O, Zusman I: Immune response of rat spleen cells to a carcinogen and to vaccination with anti-p53 polyclonal antibodies. Anticancer Res 18: 273-282, 1998.
60. Umansky SR: Apoptosis: Molecular and cellular mechanisms (A review). Molec Biol (Moscow) 30: 285-295, 1996.
61. Goldsworthy TL, Conolly RB, and Franssonsteen R: Apoptosis and cancer risk assessment. Mutat Res 365 (Suppl.1-3): 71-90, 1996.
62. Manning FCR, and Patierno SR: Apoptosis: Inhibitor or instigator of carcinogenesis. Cancer Invest 14: 455-465, 1996.
63. Martin SJ and Green DR: Apoptosis and cancer. The failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 18: 137-153, 1995.
64. Harris CC: p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 17: 1187-1198, 1996.
65. Jacks T: Lessons from the p53 mutant mouse. J Cancer Res Clin Oncol 122: 319-327, 1996.
66. Green DR, McGahon A, and Martin SJ: Regulation of apoptosis by oncogenes. J Cell Biochem 60: 33-38, 1996.
67. Ragupathi G: Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 43: 152-157, 1996.
68. Whitheley LO, Hudson L and Pretlow TP. Aberrant crypt foci in the colonic mucosa of rats treated with a genotoxic and nongenotoxic colon carcinogen. Toxicol Pathol 24: 681-689, 1996.
69. Choi HJ, Jung IK, Kim SS and Hong SH: Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas. Dis Colon Rectum 40: 51-58, 1997.
70. Takei K, Watanabe H, Itoi T and Saito T: p53 and Ki-67 immunoreactivity and niclear morphometry of "carcinoma-inadenoma" and adenoma of the gall-bladder. Pathol Int 46: 426-435, 1996.
71. Sun XF, Carstensen JM, Zhang H, Arbman G and Nordenskjold B: Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 32A: 1963-1967, 1996.
72. Wang J, Coltrera MD and Gown AM: Abnormalities of p53 and p 110 (RB) tumor suppressor gene expression in human soft tissue tumors: Correlations with cell proliferation and tumor grade. Modern Pathol 8: 837-842, 1995.
73. Zusman I, Reifen R, Livni O, Smirnoff P, Gurevich P, Sandier B, Nyska A, Gal R, Tendler Y and Madar Z: Role of apoptosis, proliferating cell nuclear antigen and p53 protein in chemically induced colon cancer in rats fed corncob fiber treated with the fungus Pleurotus ostreatus. Anticancer Res 17: 2105-2114, 1997.
74. Mueller H and Eppenberger U: The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 16: 3845-3848, 1996.
75. Yamada K and Wada R. Expression of apoptosis-related antigen Le(Y) in superficial colorectal adenoma and adenocarcinoma. Int J Oncol 9: 653-658, 1996.
76. Grekou AN, Toliou T, Stravoravdi P, Patakiouta F, Tsoukalas T, Pinakidis M and Keramidas G: Correlation of apoptosis with the distribution and composition of lymphocytic infiltrate in human breast carcinomas. Anticancer Res 16: 3991-3995, 1996.
77. Soini Y and Paako P: Extent of apoptosis in relation to p53 and be 1 -2 expression in germ cell tumors. Hum Pathol 27: 1221-1226, 1996.
78. Hayash R, Luk H, Horio D and Dashwood R: Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-f] quinoline. Cancer Res 56: 4307-4310, 1996.
79. Zheng ZY, Bernstein H, Bernstein C, Payne CM, Martinez JD and Gerner EW: Bile acid activation of the gadd153 promoter and of p53-independent apoptosis: relevance to colon cancer. Cell Death Different 3: 407-414, 1996.
80. Ge XK, Yannai S, Rennert G, Gruener N and Fares FA: 3,3'-indolylmethane induce apoptosis in human cancer cells. Biochem Biophys Res Comm 228: 153-158, 1996.
81. Losman MJ, Leung S-O, Shih LB, Shevitz J, Shukla R, Harada I., Goldenberg DM, Hansen HJ: Development and evaluation of the specificity of a rat monoclonal anti-idiotypic antibody WN to an anti-B-cell Iymphoma monoclonal antibody LL2. Cancer Res 55: 5978s-5982s, 1995.
82. Kovacsovics-Bancovski M, Clark K, Benacerraf B, Rock KL: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90: 4942-4946, 1993.
83. Timens W: The human spleen and immune system: Not just another lymphoid organ. Res Immunol 142: 316-320, 1991.
84. Eertwegh van der AJ, Boersma WJ, Chaessen E: Immunological functious and in vivo cell-cell interactions of T cells in the spleen. Crit Rev Immunol 11: 337-348, 1992.
85. Balogh P and Kumanovics A: Tissue-associated phenotypic heterogeneity of peripheral B cells in mice. Immunol 86: 560-567, 1995.
86. Zhang J and Russell SJ: Vectors for cancer gene therapy. Cancer Metast Rev 15: 385-401, 1996.
87. Laman JD, Claassen E, Noelle RJ: Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 16: 59-108, 1996.
88. Grewal IS and Flavell RA: A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 17: 409-414, 1996.
89. Llopis MJP, Harms G, Hardonk MJ and Timens W: Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21 positive splenic marginal zone B cells and follicular dendritic cells. J Allergy Clin Immunol 97: 1015-1024, 1996.
90. Braun J and Stiehm ER: The B-lymphocyte system. In: Stiehm ER (ed), Immunologic Disorders in Infants and Children. Saunders, Philadelphia, 1995, pp. 35-74.
91. Nieuwenhuis P and Opstelten D: Functional anatomy of germinal centers. Am J Anat 70: 421-435, 1984.
92. Grekou AN, Toliou T, Stravoravdi P, Patakiouta F, Tsoukalas T, Pinakidis M and Keramidas G: Correlation of apoptosis with the distribution and composition of Iymphocytic infiltrate in human breast carcinomas. Anticancer Res 16: 3991-3996, 1996.
93. Loresvazquez B, Pachecocarracedo M, Olivermorales J, Paradagonzalez P and Gambondeze F: Lymphocyte subpopulations of regional lymph nodes in human colon and gastric adenocarcinomas. Cancer Immunol Immunother 42: 339-342, 1996.
94. Corr M, Lee DJ, Carson DA and Tighe H: Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184: 1555-1560, 1996.
95. Amano T, Nakazawa M, Oshima T, Bosshardt SC and Colley DG: Cross-reactive idiotypes on rabbit anti-SEA antibodies stimulate antiidiotype spleen and lymph node cell responses of mice infected with Schistosoma mansoni. Parasite Immunol 18: 21-28, 1996.
96. Oprea M and Perelson AS. Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J Theoret Biol 181: 215-236, 1996.
97. Marland G, Bakker AB, Adema GJ and Figdor CG: Dendritic cells in immune response induction. Stem Cells 14: 501-507, 1996.
98. Douglas SD and Yoder MC: The mononuclear phagocyte and dendritic cell system. In: Stiehm ER (ed.), Immunologic Disorders in Infants and Children. Saunders, Philadelphia, 1995, pp. 113-132.
99. Grouard G, Durand I, Filgueira L, Banchereau J and Liu YJ: Dendritic cells capable of stimulating T cells in germinal centres. Nature 384: 364-367, 1996.
100. Chatterjee M: Nutrients and cancer. Cancer J 9: 287-290, 1996.
101. Statland B: Nutrition and cancer. Clin Chem 35: 1587-1594, 1992.
102. El-Bayoumy K: Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis 15: 2395-2420, 1994.
103. Good RA, Lorenz E, Eugelman R, Day NK: Experimental approaches to nutrition and cancer: fats, calories, vitamins and minerals. Med Oncol Tumor Pharmacother 7: 183-192, 1990.
104. Greenwald P: Colon cancer overview. Cancer 70: 1206-1215, 1992.
105. Randall E, Marshall JR, Brasure J, Graham S: Dietary patterns and colon cancer in western New York. Nutr Cancer 18: 265-276, 1993.
106. Sugimura T: Food as source of complex mixtures of mutagens and carcinogens. In: Vainio H, Sorsa M and McMichael AJ (eds), Complex Mixtures and Cancer Risk. Int. Agency Res. Cancer, Lyon, 1990, pp. 399-407.
107. Madar Z, Weiss O, Timar B, Gurevich P, Zusman I: The effects of high-fiber diets on chemically induced colon cancer in rats. Cancer J 9: 207-211, 1996.
108. Zusman I, Gurevich P, Madar Z, Nyska A, Korol D, Timar B, Zuckerman A:. Tumor-promoting and tumor-protective effects of high-fat diets on chemically induced mammary cancer in rats. Anticancer Res 17: 349-356, 1997.
109. Burstein MJ: Dietary factors related to colorcctal neoplasms. Surg Clin North Am 73: 13-29, 1993.
110. Kono S, Imanishi K, Shinchi K, Yanai F: Relationship of diet to small and large adenomas of the sigmoid colon. Jap J Cancer Res 84: 13-19, 1993.
111. Giovannucci F, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 54: 2390-2397, 1994.
112. Steele GD: The national cancer data base report on colorectal cancer. Cancer 74: 1979-1989, 1994:
113. Yam D, Eliraz A, Berry EM: Diet and disease - The Israel paradox: Possible dangers of a high omega-6 polyunsaturated fatty acid diet. Isr J Med Sci 32: 1134-1143, 1996.
114. Thorup I, Meyer O, Kristiansen E: Effect of a dietary-fiber (beet fiber) on dimethylhydrazine-induced colon cancer in Wistar rats. Nutr Cancer 17: 251-261, 1992.
115. Madar Z, Timar B, Nyska A, Zusman I: Effects of high-fiber diets on pathological changes in DMH-induced rat colon cancer. Nutr Cancer 20: 87-96, 1993.
116. Ausman LM: Fiber and colon cancer - Does the current evidence justify a preventive policy? Nutr Rev 57: 57-63, 1993.
117. Heitman DW, Ord VA, Hunter KE, Camerun IL: Effect of dietary cellulose on cell proliferation and progression of 1,2-dimethylhydrazine-induced colon Carcinogenesis in rats. Cancer Res 49: 5581-5589, 1989.
118. Kritchevsky D and Klurfeld DM: Interaction of fiber and energy registration in experimental colon carcinogens. Cancer Lett 114: 51-52, 1997.
119. Vang O, Rasmussen BF, Andersen O: Combined effects of complex mixtures of potentially anticarcinogenic compounds on antioxidant enzymes and carcinogen metabolizing enzymes in the rat. Cancer Lett 114: 283-286, 1997.
120. Sandler RS, Lyles CM, Peipins LA, Mcauliffe CA, Woosley JT, Kupper LL: Diet and risk of colorectal adenomas - macronutritients, cholesterol, and fiber. J Natl Cancer Inst 85: 884-891, 1993.
121. Persky V and Vanhorn L: Epidemiology of soy and cancer: Perspectives and directions. J Nutr 125: S709-S712, 1995.
122. Hawrylewicz EJ, Zapata JJ, Blair WH: Soy and experimental cancer: Animal studies. J Nutr 125: S698-S708, 1995.
123. Alink GM, Kuiper HA, Hollanders VMH, Koeman JH: Effect of heat processing and of vegetables and fruit in human diets on 1,2-dimethylhydrazine- induced colon carcinogenesis in rats. Carcinogenesis 14: 519-524, 1993.
124. Chapkin RS, Gao J, Lee DYK, Lupton JR: Dietary fibers and fats alter rat colon protein kinase C activity - correlation to cell protliferation. J Nutr 123: 649-655, 1993.
125. Craven PA, DeRubertis FR: Alterations in protein kinase C in 1,2-dimethylhydrazine induced colonic carcinogenesis. Cancer Res 52: 2216-2221, 1992.
126. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava, S, Vernum B,. Liu ET, Cance WG: Receptor tyrosine kinase expressed in metastatic colon cancer. Int J Cancer 60: 791-797, 1995.
127. Pongracz J, Clark P, Neoptolemos JP, Lord JM: Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 61: 35-39, 1995.
128. Desai TK, Parikh N, Bronstein JC, Luk GD, Bull AW: Failure of rectal ornithine decarboxylase to identify adenomatous polyp status. Gastroenterol 103: 1562-1567, 1992.
129. Suzuki S, Okayasu I, Kudo H, Kuwa K, Yishimura S, Mitamura T, Sakamoto S: Pathological and enzymatic features of 1,2-dimethylhydrazine induced colorectal carcinomas in rats. Oncol Rep 2: 723-726, 1995.
130. Severini G, Diana L, Digiovannandrea R, Tirelli C: A study of serum glycosides in cancer. J Cancer Res Clin Oncol 121: 61-63, 1995.
131. Ohkami H, Tazawa K, Yamashita I, Shimizu T, Murai K, Kobashi K, Fujimaki M: Effects of apple pectin on fecal bacterial enzymes in azoxymethane-induced rat colon carcinogenesis. Jap J Cancer Res 86: 523-529, 1995.
132. Sakamoto J, Nakaji S, Sugawara K, Twane S, Munakata A: Comparison of resistant starch with cellulose diet on 1,2-dimethylhydrazine-induced colonic carcinogenesis in rats. Gastroenterol 110: 116-120, 1996.
133. Christl SU, Bartram HP, RUckert A, Scheppach W, Kasper W: Influence of starch fermentation on bile acid metabolism by colonic bacteria. Nutr Cancer 24: 67-75, 1995.
134. Vanmunster IP, Tangerman A, Nagengast FM: Effects of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. Dig Dis Sci 39: 834-842, 1994.
135. Alberts DS, Ritenbaugh C, Story JA, Aickin M, Reesmcgee S, Buller MK, Atowood J, Phelps J, Ramanujam PS, Bellapravalu S, Patel J, Bettinger L, Clark L: Randomized, double-blinded, placebocontrolled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps. J Natl Cancer Inst 88: 81-92, 1996.
136. Nyska A, Zusman I, Klein T, Sheila N, Weiss O, Madar Z, Klein B:. Assessment of the nucleolar organizer regions by automated image analysis in benign and malignant colonic tumorous and adjacent tissues in rats. J Com Path 113: 45-50, 1995.
137. Scott N, Bell SM, Sagar P, Blair GF, Dixon MF, Quirke P: p53 expression and K-ras mutation in colorectal adenomas. Gut 34: 621-624, 1993.
138. Dees C and Travis C: Hyperphosphorylation of p53 induced by benzene, toluene, and chloroform. Cancer Lett 84: 117-123, 1994.
139. Dix B, Robbins P, Carrello S, House A, Iacopetta B: Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70: 585-590, 1994.
140. Baretton GB, Vogt M, Diebold J, Blasenbreu S, Schneiderbanger K, Lohrs U: p53-expression and chromosome 17-copy number in colorectal adenomas: correlations to histomorphology and DNA-ploidy. Oncol Rep 3: 357-363, 1996.
141. Cummings JH, Bingham SA, Heaton KW, Eastwood MA: Fecal weight, colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber). Gastroenterol 103: 1783-1789, 1992.
142. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C: Sodium butyrate induces apoptosis in human colonic tumour cell lines in p53-independent pathway - Implication for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 55: 498-505, 1993.
143. Prindull G: Apoptosis in the embryo and tumorigenesis. Eur J Cancer 31A: 116-123, 1995.
144. Potter JD: Reconciling the epidemiology, physiology, and molecular biology of colon cancer. JAMA 268: 1573-1577, 1992.
145. Parkin DM: Cancer in developing countries. Cancer Surveys 9/20: 519-561, 1994.
146. Spicer DV and Pike MC: Epidemiology of breast cancer. In: Treatment of the Postmenopausal Woman: Basic and Clinical Lobo RA (ed). Aspect. Raven Press, New York, 1994, pp. 315-324.
147. Ursin G, Bernstein L, Pike MC: Breast cancer. Cancer Surveys 19/20: 241-264, 1994.
148. Hunter DJ and Willett WC: Diet, body build, and breast cancer. Ann Rev Nutr 14: 393-418, 1994.
149. Hill MJ: Dietary fat and cancer. Eur Cancer Prevent News 27: 4-5, 1995.
150. Chlebowski RT and Grosvenor M: The scope of nutrition intervention trials with cancer-related endpoints. Cancer 74: 2734-2738, 1994.
151. Austoker J: Cancer prevention in primary care - Screening and self examination for breast cancer. Br J Cancer 309: 168-174, 1994.
152. Kitagawa H and Noguchi M: Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz(a)antracene in rats on high- and low-fat diets. Oncol 51: 401-410, 1994.
153. Trichopoulos A, Katsouyanni K, Stuver S, Tzala L, Gnardellis C, Rimm T, Trichopoulos D: Consumption of olive oil and specific food groops in relation to breast cancer. J Natl Cancer Inst 87: 110-116, 1995.
154. Willett WC: Dietary fat and risk of breast and colon cancer. Proc Nutr Soc 53: 25-26, 1994.
155. Ip C, Scimeca, JA, Thompson HJ: Effect of timing and duration of dietary conjugated linoleic acid on mammary cancer prevention. Nutr Cancer 24: 241-247, 1995.
156. Godley PA: Essential fatty acid consumption and risk of breast cancer. Breast Cancer Res Treat 55: 91-95, 1995.
157. Welsch CW: Interrelationship between dietary lipids and calories and experimental mammary gland tumorigenesis. Cancer 74: 1055-1062, 1994.
158. Rose DP, Connolly JM, Liu XH: Effects of linoleic acid and γ-linoleic acid on the growth and metastasis of a human breast cancer cell line in nude mice and on its growth and invasive capacity in vitro. Nutr Cancer 24: 33-45, 1995.
159. Ohta N, Noguchi M, Kinoshita K, Earashi M, Minami M, Mizukami Y: The effects of high dietary fat and indomethacin on 7,12-dimethylbenz(a)antracene- induced mammary carcinomas in rats. Oncol Rep 3: 305-312, 1996.
160. Ip C, Singh M, Thompson HJ, Scimeca JA: Conjugated linoleic acid supresses mammary carcinogenesis and proliferative activity of the mammary gland in the rat. Cancer Res 54: 1212-1215, 1994.
161. Ip C, Lisk DJ, Scimeca JA: Potential of food modification in cancer prevention. Cancer Res 54: 1957S-1959S, 1994.
162. Barnes S, Grubbs C, Setchel, KDR, Carlson J: Soybeans inhibit mammary tumors in models of breast cancer. In: Pariza MW, Aeschbacher HU, Felton JS, Sato S (eds). Mutagens and Carcinogens in the Diet. Wiley-Liss, New York, 1990, pp. 239-253.
163. Cohen LA, Chen-Backlund JY, Sepkovic DW, Sugie S: Effect of varying proportions of dietary menhaden and corn oil on experimental rat mammary tumor promotion. Lipids 28: 449-456, 1993.
164. Fisher SM, Conti CJ, Locniskar M, Beluty MA, Maldve RE, Lee ML, Leyton J, Slaga TJ, Bechtel DII: The effect of dietary fat on the rapid development of mammary tumors induced by 7,12-dimethylbenz(a)antracene in SENCAR mice. Cancer Res 52: 662-666, 1992.
165. Lipworth L, Martinez ME, Angell J, Hsieh CC, Trichopoulos D: Olive oil and human cancer: An assessment of the evidence. Prevent Med 26: 181-190, 1997.
166. Bell SJ, Bradley D, Forse RA, Bistrian BR: The new dietary fats in health and disease. J Am Dietetic Assoc 97: 28-286, 1997.
167. Johanning GL: Modulation of breast cancer cell adhesion by unsaturated fatty acids. Nutrition 12: 810-816, 1996.
168. Rose DP, Connolly JM: Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 50: 7139-7143, 1990.
169. Martinmoreno JM, Willett WC, Gorgojo L, Banegas JR, Rodriguezartalejo F, Fernandezrodriguez JC, Maisonneuve P, Boyle P: Dietary fat, olive oil intake and breast cancer risk. Int J Cancer 58: 74-780, 1994.
170. Tinsley IJ, Schmitz JA, Pierce DA: Influence of dietary aids on the icidence of mammary tumors in the C3H mouse. Cancer Res 41: 460-1465, 1981.
171. Welsch CW, Welsch MA, Huelskamp LJ, Gonzales MJ, Vanderploeg LC: Influence of dietary fat on growth of MDA-MB231 human breast carcinomas maintained in female athymic nude mice. Int J Oncol 6: 55-64, 1995.
172. Kromhout D: The importance of N-6 and N-3 fatty acids in carcinogenesis. Medical Oncol Tumor Pharmacother 7: 173-176, 1990.
173. Derenzini M, Farabegoli F, Trere D: Relationship between interphase AgNOR distribution and nucleolar size in cancer cells. Histochemical J 24: 951-956, 1992.
174. Aubele M, Auer G, Jutting U, Falkmer U, Gais P: Prognostic value of quantitatively measured AgNORs in ductal mammary carcinoma. Analyt Quantitat Cytol Histol 16: 211-218, 1994.
175. Egan MJ, Jaubert F, Nezelof C, Scheiner C, Lallemand A, Ploton D: Nucleolar organiser regions in pathology. Br J Cancer 65: 1-7, 1992.
176. Eeles RA, Bartkova J, Lane DP, Bartek J: The role of TP53 in breast cancer development. Cancer Surveys 18: 57-75, 1993.
177. Norberg T, Jansson T, Sjogren S, Martensson C, Andreasson I, Fjallskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J: Overview of human breast cancer with focus on prognostic and predective factors with special attention on the tumour suppressor gene p53. Acta Oncol 35 (Suppl. 5): 96-102, 1996.
178. Hurliman J: Prognostic Value of p53-protein expression in breast carcinoma pathology. Res Practice 189: 996-1003, 1993.
179. Tillotson JK, Darzynkiewicz Z, Cohen LA, Ronai Z:. Effects of linoleic acid on mammary cell proliferation are associated with changes in p53 protein expression. Int J Oncol 3: 81-87, 1993.
180. Fernandes G, Chandrasekar B, Troyer DA, Venkatraman JT, Good RA: Dietary lipids and caloric restriction affect mammary tumor incidence and gene expression in mouse mammary tumor Virus/v-Ha-ras transgenic mouse. Proc Natl Acad Sci USA 92: 6494-6498, 1995.
181. Madar Z and Zusman I: The role of dietary factors in prevention of chemically-induced cancers (Review). Int J Oncol 11: 1141-1148, 1997.
182. Wilson RE, Donohue JH: Neoplasia in the colorectum: nature history and prognosis. In: Philips SF, Pemberton JH, Shorter RG (eds). The Large Interstine. Physiology, Pathophysiology and Disease. Raven Press, New York, 1991, pp. 521-547.
183. Ziegler JL: Cancer in immunocompromised host. In: Stites DP and Terr J (eds). Basic and Clinical Immunology. Appleton and Lange, Norwalk, CA, 1991, pp. 588-598.
184. Schreiber H: Tumor immunology. In: Paul WE (ed).Fundamental Immunology. Raven Press, New York:, 1993, pp. 1143-1178.
185. Fey MF: p53, myc, APC, hMSH2, ras, etc. in colorectal cancer - a never ending story! Annals Oncol 6: 961-962, 1995.
186. Zusman I: The role of p53 tumor-associated protein in colon cancer detection and prevention (Review). Int J Oncol 10: 116-120, 1997.